抗痛风药物的临床研究进展  

Advances in clinical research of anti-gout drug

作　　者：张利[1] 郭晔堃[1] 钟静芬[1] 

机构地区：[1]上海医药工业研究院,上海200437

出　　处：《上海医药》2015年第17期19-22,34,共5页Shanghai Medical & Pharmaceutical Journal

摘　　要：痛风是一种常见的风湿性疾病,目前,急性痛风常用非甾体抗炎药、秋水仙碱,但它们对伴有并发症的痛风患者无效;而在痛风发作的其他时期则可使用降尿酸药物。近年来黄嘌呤氧化酶(XOD)抑制剂和嘌呤核苷磷酸化酶(PNP)抑制剂等可抑制尿酸合成的药物成为这个领域的研究热点。本文主要介绍了白细胞介素1抑制剂(IL-1β抑制剂)、lesinurad、XOD抑制剂、PNP抑制剂的作用机制,临床效果和不良反应。Gout is a common rheumatologic disorder and non-steroidal anti-inflammatory drugs and colchicine have been currently used for its treatment during its acute attack period. Although these drugs are generally effective, it may be contraindicated especially in patients with concomitant comorbidities while urate-lowering drugs can be used during other periods. In recent years, both xanthine oxidase（XOD） and purine nucleoside phosphorylase（PNP） inhibitors have become a hot topic of research in this field. This paper describes the mechanism of action of the interleukin-1 inhibitor（IL-1c inhibitors）, lesinurad, XOD and PNP inhibitors, their clinical effects and adverse reactions.

关 键 词：XOD抑制剂 IL-1β抑制剂 lesinurad PNP抑制剂 

分 类 号：R971.1[医药卫生—药品]